All In MedTech

Device Trial Radar · NCT07662824

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Aug 20, 2028

Study completion Aug 20, 2028

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
Female only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation therapy. Urinary incontinence is common after pelvic radiation therapy and can affect daily life and well-being. Access to in-person pelvic floor physical therapy can be limited. The Flyte device is designed for in-home use to deliver a series of mechanical vibrations at a specific frequency while the pelvic floor muscles are contracting and relaxing (i.e., normal, guided Kegel exercises). This treatment is called mechanotherapy. The Flyte device may improve urinary incontinence symptoms, as well as overall quality of life among endometrial and cervical cancer survivors who have undergone radiation therapy.

Conditions

  • Cervical Carcinoma
  • Endometrial Carcinoma
  • Overactive Bladder
  • Voiding Disorders

Interventions

  • Educational InterventionOther

    Given educational handouts

  • InterviewOther

    Patients are interviewed on study

  • Flyte Medical Device Usage and EvaluationDevice

    Use Flyte device

  • Questionnaire AdministrationOther

    Participants complete questionnaires on study

  • ReferralOther

    Given referral for in-person pelvic floor physical therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants successfully completing study set up (Feasibility)Time frame: Up to 24 weeks
  2. Incidence of all serious adverse events (SAEs) including unanticipated adverse device effectsTime frame: Up to 90 days the last administration of study treatment
  3. Incidence of all device failures and malfunctionsTime frame: Up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.